Clinical trials: Severe COVID-19
Covid19, SARS-CoV Infection
RECOVAC - Long Term Efficacy and Safety of COVID-19 (SARS-CoV-2) Vaccination in Kidney Disease Patients
Rationale: COVID-19 is associated with severely increased morbidity and mortality in patients with chronic kidney disease stage G4-G5 and patients on dialysis or after kidney transplantation.
- Conditions
- Covid19, SARS-CoV Infection, Chronic Kidney Diseases
- Trial name
- LESS CoV-2 (NCT04841785)
- Testing
- mailer-based finger-prick
- Where
- Netherlands
- Volunteers
- 4,868 people
- Sponsor
- University Medical Center Groningen
COVID-19
Study of Efficacy of Different Treatment Regimens of Olokizumab
The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation.
- Trial name
- RESET (NCT05187793)
- Testing
- Olokizumab, Standard therapy
- Where
- 5 sites in Russia
- Volunteers
- 198 people
- Sponsor
- R-Pharm
Covid19
Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine
This is a randomized, parallel dose assigned, double blind, multi center, Phase II study assessing the efficacy, safety, and immunogenicity of VLP vaccine (Authentic and Alpha variants) in adults between 18 and 59 years who are…
- Trial name
- COVID-19 (NCT04962893)
- Testing
- SARS-CoV-2 VLP Vaccine-Wuhan, SARS-CoV-2 VLP Vaccine-Alpha (British) variant, SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- Ihsan GURSEL, PhD, Prof.
Covid19, SARS-CoV Infection
A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections
Prospective, observational, exploratory study exploring the relationship between passively-collected data from wearable activity devices and SARS-CoV-2 infection
- Trial name
- NCT04623138
- Where
- United States
- Volunteers
- 847 people, healthy volunteers welcome
- Sponsor
- Evidation Health
Coronavirus Disease 2019 (COVID-19)
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04545047
- Testing
- COVID-19 convalescent plasma
- Where
- 2 sites in United States
- Volunteers
- 5,044 people
- Sponsor
- VA Office of Research and Development
COVID
Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )
The primary objective of this trial is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical ventilation in patients with…
- Trial name
- FORCE (NCT04371367)
- Testing
- avdoralimab
- Where
- France
- Volunteers
- 208 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2
Treatment of SARS Caused by COVID-19 With Ruxolitinib
In December 2019, a new virus emerged in Wuhan, China rapidly becoming a pandemic with registered cases above 800,000 around the world. The virus is now known as SARS-CoV2 calling its disease coronavirus-19 or COVID-19.
- Trial name
- NCT04334044
- Testing
- Ruxolitinib Oral Tablet
- Where
- Mexico
- Volunteers
- 77 people
- Sponsor
- Grupo Cooperativo de Hemopatías Malignas
SARS-CoV Infection
National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE)
National cohort study of effectiveness and safety of SARS-CoV-2 vaccines (ENFORCE is an equivalence trial to evaluate the effectiveness and safety of multiple new SARS-CoV-2 vaccines approved for use in the EU, and which are…
- Trial name
- ENFORCE (NCT04760132)
- Testing
- COMIRNATY - BioNTech Manufacturing GmbH, COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH, COVID-19 Vaccine AstraZeneca suspension for injection
- Where
- 5 sites in Denmark
- Volunteers
- 7,600 people, healthy volunteers welcome
- Sponsor
- Jens D Lundgren, MD
Covid19, SARS-CoV Infection
A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition
The co-primary objectives of this study are to: 1. Determine and compare the COVID-19 antibody positivity rate in health care workers and patients without a known COVID-19 infection 2.
- Trial name
- START (NCT04573634)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Jill M Kolesar
Covid19, Myopathy
Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Immune-related Myopathy (Myasthenia Gravis and Inflammatory Myopathy) Patients ：a Prospective Observational Study
This study is a prospective observational study. We aim to investigate the safety and efficacy of inactivated SARS-CoV-2 vaccine between immune-related myopathy (myasthenia gravis and inflammatory myopathy) patients and health…
- Trial name
- NCT04941079
- Testing
- no intervention
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
SARS (Severe Acute Respiratory Syndrome), Covid19
Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19]
An initial retrospective epidemiological investigation was conducted in a city north of France after the diagnosis of the first case of COVID-19 on February 2020.
- Trial name
- COVID-OISE (NCT04644159)
- Testing
- Human biological samples
- Where
- 2 sites in France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Severe Viral Pneumonia(Not Include COVID-19)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of Menstrual blood-derived Mesenchymal Stem Cells (SC01009) injection for the treatment of severe…
- Trial name
- NCT06693362
- Testing
- Drug therapy, Standard Treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
SARS-CoV Infection
Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19
Since March 2020, the SARS-CoV type coronavirus infection (SARS-CoV-2; nCoV19; COVID-19) is considered pandemic. As early as April 2020, the World Health Organization recommended the implementation of mass screening of…
- Trial name
- SAMILCOV (NCT04550390)
- Testing
- Saliva collection
- Where
- 4 sites in France
- Volunteers
- 329 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
Sars-CoV2, Covid-19
Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the novel coronavirus disease 2019 (COVID-19) pandemic.
- Trial name
- ACICOVID (NCT04373759)
- Testing
- Cardiopulmonary resuscitation, Modified Rankin score
- Where
- 36 sites in France, Martinique
- Volunteers
- 186 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
SARS-CoV Infection
Tocilizumab in COVID-19 Lahore General Hospital
The most accepted description of severe COVID-19 disease is development and over production of pro-inflammatory cytokines. Autopsy studies have been done on COVID-19 patients proved that severe disease is resulted due to deviant…
- Trial name
- TC19LGH (NCT04560205)
- Testing
- Tocilizumab
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Lahore General Hospital
COVID-19
A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19
The effect of RESP301 as an add on treatment to SOC will be evaluated for its efficacy in reducing rate of progression to a more severe level of COVID-19 and for safety, by comparison with SOC alone in hospitalized COVID-19…
- Trial name
- NCT04460183
- Testing
- RESP301, a Nitric Oxide generating solution, Standard of Care
- Where
- 2 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- Thirty Respiratory Limited
Severe/Very Severe COVID-19 Illness
Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness
The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with severe/very severe COVID-19 illness.
- Trial name
- NCT04337359
- Testing
- Ruxolitinib
- Sponsor
- Novartis Pharmaceuticals
SARS (Severe Acute Respiratory Syndrome), Cytokine Storm
Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
COVID-19 may cause severe pneumonitis that require ventilatory support in some patients, the ICU mortality is as high as 62%. Hospitals do not have enough ICU beds to handle the demand and to date there is no effective cure.
- Conditions
- SARS (Severe Acute Respiratory Syndrome), Cytokine Storm, ARDS, Human, COVID-19
- Trial name
- COVID-19-HBO (NCT04327505)
- Testing
- Hyperbaric oxygen
- Where
- 3 sites in Germany, Sweden
- Volunteers
- 34 people
- Sponsor
- Karolinska Institutet
Severe COVID-19 Pneumonia
ANTIcoagulation in Severe COVID-19 Patients
Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease due to a state of profound inflammation…
- Trial name
- ANTICOVID (NCT04808882)
- Testing
- Tinzaparin, Low dose prophylactic anticoagulation, Tinzaparin, High dose prophylactic anticoagulation, Tinzaparin,Therapeutic anticoagulation
- Where
- France
- Volunteers
- 353 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SARS-CoV Infection
Recovery of Exertion Ability Following COVID-19 Infection in Military Staff
The Paris Fire Brigade staff have been particularly exposed to COVID-19 due to rescue and care activities for victims at risk in Paris area (where the virus was actively circulating).
- Trial name
- CovEx (NCT04548505)
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.